Evolus, Inc. (NASDAQ:EOLS) is Stonepine Capital Management LLC's Largest Position

Stonepine Capital Management LLC lifted its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,333,004 shares of the company's stock after purchasing an additional 154,000 shares during the quarter. Evolus accounts for approximately 24.3% of Stonepine Capital Management LLC's holdings, making the stock its biggest position. Stonepine Capital Management LLC owned approximately 9.32% of Evolus worth $56,157,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Walleye Capital LLC raised its position in Evolus by 650.1% in the 3rd quarter. Walleye Capital LLC now owns 293,084 shares of the company's stock worth $2,679,000 after buying an additional 254,013 shares during the last quarter. Brandywine Global Investment Management LLC raised its position in Evolus by 1.9% in the 3rd quarter. Brandywine Global Investment Management LLC now owns 158,200 shares of the company's stock worth $1,446,000 after buying an additional 3,000 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Evolus in the 3rd quarter worth about $1,200,000. Graham Capital Management L.P. grew its stake in shares of Evolus by 43.1% during the 3rd quarter. Graham Capital Management L.P. now owns 37,946 shares of the company's stock valued at $347,000 after purchasing an additional 11,438 shares during the period. Finally, Swiss National Bank grew its stake in shares of Evolus by 1.8% during the 3rd quarter. Swiss National Bank now owns 93,800 shares of the company's stock valued at $857,000 after purchasing an additional 1,700 shares during the period. Hedge funds and other institutional investors own 90.69% of the company's stock.

Insider Activity at Evolus

In related news, CFO Sandra Beaver sold 5,672 shares of the business's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the transaction, the chief financial officer now directly owns 154,201 shares in the company, valued at approximately $2,146,477.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Evolus news, CFO Sandra Beaver sold 5,672 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $78,954.24. Following the completion of the transaction, the chief financial officer now directly owns 154,201 shares in the company, valued at approximately $2,146,477.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rui Avelar sold 27,603 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $384,233.76. Following the completion of the transaction, the insider now owns 372,288 shares of the company's stock, valued at $5,182,248.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,969 shares of company stock worth $831,005. 5.40% of the stock is owned by company insiders.

Evolus Price Performance

Shares of NASDAQ:EOLS traded down $0.01 during mid-day trading on Tuesday, reaching $13.29. 277,507 shares of the company traded hands, compared to its average volume of 648,228. The company's 50 day moving average price is $13.77 and its 200-day moving average price is $11.01. The firm has a market cap of $770.02 million, a PE ratio of -12.19 and a beta of 1.45. Evolus, Inc. has a 52 week low of $7.07 and a 52 week high of $15.43.

Evolus (NASDAQ:EOLS - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). The company had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. On average, research analysts predict that Evolus, Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on EOLS. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, December 20th. Barclays upgraded Evolus from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $10.00 to $16.00 in a research note on Monday, January 29th. Finally, HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Friday, March 1st.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.